FK-614, a selective peroxisome proliferator-activated receptor γ agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs

Metabolism: Clinical and Experimental

Volumn 54, Issue 9, 2005, Pages 1250-1258

  Uchino, Hiroshi ^a,c   Kim, Tony ^a   Lam, Tony K T ^a   Yoshii, Hidenori ^c   Klement, Peter ^b   Williams, Wendy ^b   Kawamori, Ryuzo ^c   Giacca, Adria ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOXAN; BENZIMIDAZOLE DERIVATIVE; CARBON 14; FK 614; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TRACER; UNCLASSIFIED DRUG; URANIUM;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATHETERIZATION; CONTROLLED STUDY; DIET RESTRICTION; DOG; DRUG EFFECT; EXPERIMENT; FATTY LIVER; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN CLEARANCE; INSULIN INFUSION; INSULIN SENSITIVITY; ISOTOPE LABELING; MALE; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BENZIMIDAZOLES; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, EXPERIMENTAL; DOGS; FATTY ACIDS, NONESTERIFIED; GLUCAGON; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN, ISOPHANE; LIVER; MALE; PPAR GAMMA; TRITIUM;

EID: 23944483470     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2005.04.012     Document Type: Article

References (46)

1. R.R. Henry Thiazolidinediones Endocrinol Metab Clin North Am 26 1997 553 573
2. J.M. Lehmann, L.B. Moore, and T.A. Smith-Oliver An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma) J Biol Chem 270 1995 12953 12956
3. T. Shibata, K. Matsui, and K. Nagao Pharmacological profiles of a novel oral antidiabetic agent. JTT-501, an isoxazolidinedione derivative Eur J Pharmacol 364 1999 211 219
4. T.M. Willson, J.E. Cobb, and D.J. Cowan The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones J Med Chem 39 1996 665 668
5. K. Murakami, K. Tobe, and T. Ide A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats Diabetes 47 1998 1841 1847
6. Y. Fukui, S. Masui, and S. Osada A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice Diabetes 49 2000 759 767
7. S.L. Suter, J.J. Nolan, and P. Wallace Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects Diabetes Care 15 1992 193 203
8. M. Niwa, S. Rashid, and K. Shum Effect of JTT-501 on net hepatic glucose balance and peripheral glucose uptake in alloxan-induced diabetic dogs Metabolism 49 2000 862 867
9. H. Minoura, S. Takeshita, and M. Ita Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer. FK614 Eur J Pharmacol 494 2004 273 281
10. M. Matsuhisa, Z.Q. Shi, and C. Wan The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs Diabetes 46 1997 224 231
11. G. Hetenyi Jr., C. Gauthier, and M. Byers Phlorizin-induced normoglycemia partially restores glucoregulation in diabetic dogs Am J Physiol 256 1989 E277 E283
12. S.R. Myers, O.P. McGuinness, and D.W. Neal Intraportal glucose delivery alters the relationship between net hepatic glucose uptake and the insulin concentration J Clin Invest 87 1991 930 939
13. E. Ferrannini, O. Bjorkman, and G.A. Reichard Jr. The disposal of an oral glucose load in healthy subjects. A quantitative study Diabetes 34 1985 580 588
14. B.A. Adkins, S.R. Myers, and G.K. Hendrick Importance of the route of intravenous glucose delivery to hepatic glucose balance in the conscious dog J Clin Invest 79 1987 557 565
15. R.A. DeFronzo, J.D. Tobin, and R. Andres Glucose clamp technique: a method for quantifying insulin secretion and resistance Am J Physiol 237 1979 E214 E223
16. D.T. Finegood, R.N. Bergman, and M. Vranic Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates Diabetes 36 1987 914 924
17. D.C. Bradley, G.M. Steil, and R.N. Bergman Quantitation of measurement error with Optimal Segments: basis for adaptive time course smoothing Am J Physiol 264 1993 E902 E911
18. O. Bjorkman, P. Miles, and D. Wasserman Regulation of glucose turnover during exercise in pancreatectomized, totally insulin-deficient dogs. Effects of beta-adrenergic blockade J Clin Invest 81 1988 1759 1767
19. E. Ferrannini, J. Wahren, and O.K. Faber Splanchnic and renal metabolism of insulin in human subjects: a dose-response study Am J Physiol 244 1983 E517 E527
20. M.M. Hennes, A. Dua, and A.H. Kissebah Effects of free fatty acids and glucose on splanchnic insulin dynamics Diabetes 46 1997 57 62
21. D.E. Kelley, T.M. McKolanis, and R.A. Hegazi Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance Am J Physiol Endocrinol Metab 285 2003 E906 E916
22. A. Seppala-Lindroos, S. Vehkavaara, and A.M. Hakkinen Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men J Clin Endocrinol Metab 87 2002 3023 3028
23. T. Goto, T. Onuma, and K. Takebe The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects Int J Obes Relat Metab Disord 19 1995 841 845
24. J.G. Kral, K. Lundholm, and P. Bjorntorp Hepatic lipid metabolism in severe human obesity Metabolism 26 1977 1025 1031
25. M. Bedoucha, E. Atzpodien, and U.A. Boelsterli Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones J Hepatol 35 2001 17 23
26. O. Gavrilova, M. Haluzik, and K. Matsusue Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass J Biol Chem 278 2003 34268 34276
27. K. Matsusue, M. Haluzik, and G. Lambert Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes J Clin Invest 111 2003 737 747
28. S. Yu, K. Matsusue, and P. Kashireddy Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression J Biol Chem 278 2003 498 505
29. R.A. Memon, L.H. Tecott, and K. Nonogaki Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice Endocrinology 141 2000 4021 4031
30. S.H. Caldwell, E.E. Hespenheide, and J.A. Redick A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis Am J Gastroenterol 96 2001 519 525
31. H. Minoura, S. Takeshita, and T. Yamamoto Ameliorating effect of FK-614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rats 2005 [submitted]
32. E. Bugianesi, C. Zannoni, and E. Vanni Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis 36 2004 165 173
33. A.N. Peiris, R.A. Mueller, and G.A. Smith Splanchnic insulin metabolism in obesity. Influence of body fat distribution J Clin Invest 78 1986 1648 1657
34. H.J. Adrogue, J. Pena, and J.P. Comstock Glyburide increases the secretion, tissue uptake, and action of insulin in conscious normal dogs Metabolism 45 1996 579 586
35. L.C. Morin-Papunen, I. Vauhkonen, and R.M. Koivunen Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study J Clin Endocrinol Metab 85 2000 3161 3168
36. K. Osei, S. Rhinesmith, and T. Gaillard Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 diabetes: new insights on mechanisms of action Metabolism 52 2003 565 572
37. M. Tiikkainen, A.M. Hakkinen, and E. Korsheninnikova Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes Diabetes 53 2004 2169 2176
38. J. Dolais-Kitabgi, F. Alengrin, and P. Freychet Sulphonylureas in vitro do not alter insulin binding or insulin effect on amino acid transport in rat hepatocytes Diabetologia 24 1983 441 444
39. J.M. Lord, T.W. Atkins, and C.J. Bailey Effect of metformin on hepatocyte insulin receptor binding in normal, streptozotocin diabetic and genetically obese diabetic (ob/ob) mice Diabetologia 25 1983 108 113
40. C. Hofmann, K. Lorenz, and J.R. Colca Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone Endocrinology 129 1991 1915 1925
41. Y. Sugiyama, Y. Shimura, and H. Ikeda Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats Arzneimittelforschung 40 1990 436 440
42. M. Tominaga, M. Igarashi, and M. Daimon Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats Endocr J 40 1993 343 349
43. C. Furnsinn, and W. Waldhausl Thiazolidinediones: metabolic actions in vitro Diabetologia 45 2002 1211 1223
44. C.F. Burant, S. Sreenan, and K. Hirano Troglitazone action is independent of adipose tissue J Clin Invest 100 1997 2900 2908
45. P. Dandona, and A. Aljada A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis Am J Cardiol 90 2002 27G 33G
46. L.G. Fryer, A. Parbu-Patel, and D. Carling The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways J Biol Chem 277 2002 25226 25232